Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › lymphatic filariasis

Lymphatic filariasis

Part of Filariasis

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for lymphatic filariasis

5 trials tracked for lymphatic filariasis: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 143 citations.

5Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 1 Other / NA 2
  1. Phase 3 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed · 143 cited
  2. Phase 3 Moxidectin for LF, Cote d'Ivoire (DOLF) Completed · 10 cited
  3. Phase 2 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis Completed
  4. N/A Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed
  5. N/A Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Lymphatic filariasis: what the trials found

Ivermectin is an established intervention for the treatment of lymphatic filariasis, supported by large-scale Phase 3 clinical trials. These studies confirm its role in managing the condition with significant sample sizes.

The evidence base for Ivermectin is robust across multiple phases of investigation, establishing it as a primary pharmacological approach for patients with lymphatic filariasis.

Recent results — preliminary, needs further review

  • Albendazole has been investigated for microfilarial clearance and adult worm burden reduction, but results are not yet corroborated in large-scale established trials.
  • Preliminary data on Albendazole suggests potential impacts on microfilarial counts at 1 year and adult worm burdens at 2 years, though these findings remain unconfirmed.

For the clinician treating this condition

  • Ivermectin is the primary established treatment for lymphatic filariasis based on Phase 3 clinical evidence.
  • While Albendazole shows promise in preliminary studies regarding parasite burden, it currently lacks the confirmed status of Ivermectin.

AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic scoping review shows declining filarial infection prevalence in Latin America from 1946 to 2025
Dermatology Cohort
Systematic scoping review shows declining filarial infection prevalence in Latin America from 1946 to 2025 Filaria Rates Drop After Mass Drug Campaigns
This systematic scoping review synthesizes data on lymphatic filariasis, onchocerciasis, and mansonellosis across Latin America from 1946 to…
Infection rates for disfiguring parasitic diseases have dropped sharply in parts of Latin America after years of mass drug campaigns, but on…
Frontiers Apr 25, 2026
Cross-sectional review of mass drug administration impact on lymphatic filariasis elimination in Nepal
Infectious Disease
Cross-sectional review of mass drug administration impact on lymphatic filariasis elimination in Nepal Mass drug administration reduces lymphatic filariasis in most Nepal districts
This cross-sectional epidemiological monitoring survey review assesses lymphatic filariasis transmission in six endemic districts of Nepal f…
A survey of over 7,000 people in Nepal found that mass drug administration lowered infection rates in most areas, though three sites still n…
medRxiv Apr 24, 2026